HOXA5 silencing via DNA methylation reveals the critical role of HOX gene deregulation in oral carcinogenesis
Abstract
HOXA5 , a member of the HOX family, has been characterized as a tumor suppressor in several cancers. However, its regulation and role in oral cancer (OC) remain unclear. HOXA5 expression was assessed by transcriptome analysis and qRT-PCR, while methylation was evaluated using methyl-capture sequencing and bisulfite Sanger sequencing in a clinical cohort comprising OPMD, LN(-) and LN(+) groups and in vitro models. The effects of DNA methylation and retinoic acid were examined using DNMT inhibitors (DNMTi) and/or retinoic acid (RA). Promoter activity and RARB occupancy were assessed by dual-luciferase reporter and ChIP-qPCR assays, respectively. Effects of ectopic HOXA5 expression were evaluated using functional assays, whole-transcriptome profiling, and in-silico analyses. HOXA5 was upregulated and relatively hypomethylated in OPMD and the dysplastic DOK cell line, whereas its expression did not differ between LN(-) or LN(+) tumors and matched normal tissues despite increased promoter methylation. In SCC9 cells, HOXA5 was downregulated and promoter hypermethylated. Weak but significant inverse correlations between expression and promoter methylation were observed. DNMTi and/or RA treatment reversed HOXA5 expression. HOXA5- EPD2 region showed the highest promoter activity and RARB occupancy at the promoter regions was validated. HOXA5 overexpression reduced proliferation, migration, and invasion, while inducing S-phase arrest and apoptosis. Transcriptome and enrichment analyses identified pathways associated with cancer-related phenotypes, while protein interaction and in silico drug sensitivity analyses identified candidate drug-gene associations for further investigation in OC. Our findings support a role for DNA methylation in HOXA5 regulation and suggest tumor-suppressive properties of HOXA5 in OC.
Related
- Acidic bile salt-induced DNA methylation promotes APE1 upregulation through miR-128-3p silencing in esophageal adenocarcinoma
- CRISPRi-mediated silencing of racR reveals molecular strategies for surviving lethal stress coupled to Rac prophage excision
- Urinary TAGMe methylation enables preoperative risk stratification and reveals enhancer‑mediated regulation in urothelial carcinoma
- Single-Molecule Nanopore Sequencing of the TERT Core Promoter CpG Island Reveals PQS-Associated Strand Asymmetry of De Novo Methylation and Its Modulation by Photo-Oxidation
- Epigenome-Wide DNA Methylation Profiling of Matched Primary Breast Cancers and Brain Metastases Reveals Epigenetic Markers linked to Metastatic Progression: A Preliminary Study.
BibTeX
@article{basavarajappa2026hoxa5,
title = {{HOXA5 silencing via DNA methylation reveals the critical role of HOX gene deregulation in oral carcinogenesis}},
author = {Dhanraj Salur Basavarajappa and Faisal Alhedyan and Keith Hunter and Helen Colley and Stuart Hunt and A. N. Naveena Kumar and Sanjiban Chakrabarty and Raghu Radhakrishnan},
journal = {Scientific Reports},
year = {2026},
month = oct,
doi = {10.1038/s41598-026-73663-9},
url = {https://www.nature.com/articles/s41598-026-73663-9},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - HOXA5 silencing via DNA methylation reveals the critical role of HOX gene deregulation in oral carcinogenesis
AU - Dhanraj Salur Basavarajappa
AU - Faisal Alhedyan
AU - Keith Hunter
AU - Helen Colley
AU - Stuart Hunt
AU - A. N. Naveena Kumar
AU - Sanjiban Chakrabarty
AU - Raghu Radhakrishnan
PY - 2026
DA - 2026/10/11
JO - Scientific Reports
DO - 10.1038/s41598-026-73663-9
UR - https://www.nature.com/articles/s41598-026-73663-9
AB - HOXA5 , a member of the HOX family, has been characterized as a tumor suppressor in several cancers. However, its regulation and role in oral cancer (OC) remain unclear. HOXA5 expression was assessed by transcriptome analysis and qRT-PCR, while methylation was evaluated using methyl-capture sequencing and bisulfite Sanger sequencing in a clinical cohort comprising OPMD, LN(-) and LN(+) groups and in vitro models. The effects of DNA methylation and retinoic acid were examined using DNMT inhibitors (DNMTi) and/or retinoic acid (RA). Promoter activity and RARB occupancy were assessed by dual-luciferase reporter and ChIP-qPCR assays, respectively. Effects of ectopic HOXA5 expression were evaluated using functional assays, whole-transcriptome profiling, and in-silico analyses. HOXA5 was upregulated and relatively hypomethylated in OPMD and the dysplastic DOK cell line, whereas its expression did not differ between LN(-) or LN(+) tumors and matched normal tissues despite increased promoter methylation. In SCC9 cells, HOXA5 was downregulated and promoter hypermethylated. Weak but significant inverse correlations between expression and promoter methylation were observed. DNMTi and/or RA treatment reversed HOXA5 expression. HOXA5- EPD2 region showed the highest promoter activity and RARB occupancy at the promoter regions was validated. HOXA5 overexpression reduced proliferation, migration, and invasion, while inducing S-phase arrest and apoptosis. Transcriptome and enrichment analyses identified pathways associated with cancer-related phenotypes, while protein interaction and in silico drug sensitivity analyses identified candidate drug-gene associations for further investigation in OC. Our findings support a role for DNA methylation in HOXA5 regulation and suggest tumor-suppressive properties of HOXA5 in OC.
SN - 2045-2322
ER -